Wells Fargo & Company Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $10.00

Health Catalyst (NASDAQ:HCAT) had its price objective dropped by stock analysts at Wells Fargo & Company from $13.00 to $10.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 70.65% from the company’s current price.

HCAT has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Royal Bank of Canada cut their price target on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a report on Wednesday, January 8th. Stephens upped their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.91.

Health Catalyst Stock Up 6.7 %

Health Catalyst stock traded up $0.37 during midday trading on Tuesday, hitting $5.86. 668,066 shares of the stock were exchanged, compared to its average volume of 843,108. Health Catalyst has a 1 year low of $5.35 and a 1 year high of $10.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market cap of $356.58 million, a P/E ratio of -4.35 and a beta of 1.36. The company has a 50 day moving average price of $7.50 and a two-hundred day moving average price of $7.53.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share. On average, sell-side analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Transactions at Health Catalyst

In other Health Catalyst news, CFO Jason Alger sold 19,599 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the transaction, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at $721,443.84. The trade was a 18.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Benjamin Landry sold 19,268 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the sale, the general counsel now owns 72,250 shares in the company, valued at $601,120. The trade was a 21.05 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,169 shares of company stock worth $639,174. 2.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dynamic Advisor Solutions LLC acquired a new position in Health Catalyst during the 4th quarter worth $180,000. Inspire Investing LLC lifted its holdings in Health Catalyst by 14.2% in the fourth quarter. Inspire Investing LLC now owns 56,379 shares of the company’s stock worth $399,000 after purchasing an additional 7,019 shares during the period. SG Americas Securities LLC grew its position in Health Catalyst by 21.7% in the 4th quarter. SG Americas Securities LLC now owns 27,382 shares of the company’s stock valued at $194,000 after buying an additional 4,874 shares in the last quarter. Avanza Fonder AB acquired a new position in Health Catalyst during the 4th quarter valued at about $184,000. Finally, Franklin Resources Inc. raised its position in shares of Health Catalyst by 5.8% during the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock worth $857,000 after buying an additional 5,687 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.